KYVERNA THERAPEUTICS INC
KYTXNASDAQTrading Snapshot
- Day Range
- $8.41 – $8.61
- 52-Week Range
- $2.80 – $13.67
- Volume
- $3.22B
- Avg Volume
- $2.23B
- Shares Outstanding
- 60.8M
- Next Earnings
- Aug 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $89M
- Last Q Revenue
- $24M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.28
- Dividend Yield
- —
Why Investors Own KYTX
- ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About KYVERNA THERAPEUTICS INC
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement
Kyverna Therapeutics stays a Strong Buy as miv-cel advances in SPS, gMG & refractory RA; BLA by Q4 2026 and key trial catalysts ahead. Click to know more.
Kyverna Therapeutics shares are trading higher after the company and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, autologous CD19-directed CAR T-cell therapy.
192.22 +4.44 [+2.36%]
Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract